After earning a SM from the Harvard/MIT Health Sciences and Technology program, Tom joined Siemens where he ran the global MRI business. He has also served as the CEO of the global medical operations of Carl Zeiss, the CEO of Analogic Corporation, and Chairman and CEO of LightLab Imaging, a start-up he helped to establish and sell. Tom re-joined Siemens in 2002 eventually serving as a member of the global operating board of Siemens Healthcare and the CEO of Customer Solutions Division, with 26,000 employees in over 130 countries. In April 2013, Tom started GreyBird Ventures, a consultancy and investment firm.
G. Scott Gazelle, is Professor of Radiology at Harvard Medical School and Professor in the Department of Health Policy and Management at the Harvard School of Public Health. He serves as Director Emeritus of the MGH Institute for Technology Assessment and Director of the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training. Dr. Gazelle is nationally and internationally known for his leadership role in the development and evaluation of radiofrequency tumor ablation, and more generally for his research evaluating the benefits, costs, and appropriate use of new medical technologies. He holds degrees from Dartmouth College, Case Western and Harvard University, and has authored more than 250 scientific articles, published 3 textbooks and presented numerous papers, lectures, and workshops nationally and internationally.
Russell Hirsch is a managing director at Prospect Venture Partners, a leading life sciences venture capital firm. Prior to co-founding Prospect Venture Partners II and III, he served as a venture partner and a general partner at Mayfield Fund, where he was a member of the health care technology group. While at Mayfield, he was responsible for the incubation of Intuitive Surgical Devices and participated in the incubation of Millennium Pharmaceuticals. Prior to that, he conducted biomedical research at the University of California, San Francisco, focusing on hepatitis B viral replication. Russell previously served as vice chairman of the board of Interplast and on the Genetics Advisory Council of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. He holds MD and PhD degrees in biochemistry from the University of California, San Francisco and a BA in chemistry from the University of Chicago.
Henry Lee is the Founder and Managing Partner of Hendale Fund, a growth equity oriented fund which invests in promising scalable platform companies globally. Henry has experience investing across Asian, European, and US regions and has been Chief Investment Officer for a number of large family office groups. He started his career in NY after graduating from the Wharton School of the University of Pennsylvania and worked with the Bass Brothers investment organization in Texas for many years. He currently resides in Hong Kong and serves on the board of a commercial bank in China and the Hong Kong Cancer Fund.
Mark Levin has more than 36 years of biotech and pharma experience, including 25 years building and operating leading biotech companies. In 2007, he co-founded Third Rock Ventures, where he focuses on the formation, development, and business strategy of its portfolio companies, serving as CEO during their first 12-18 months post-launch. Previously, he co-founded Mayfield Fund’s life sciences effort and was founding CEO and/or board member of its Tularik, Cell Genesys/Abgenix, Focal, Stem Cells, and Millennium Pharmaceuticals companies for 15 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an MS degree in chemical and biochemical engineering from Washington University and is a member of the National Academy of Engineering and the Friends of Personalized Medicine. He is co-founder of upSTART, a Cambridge, Mass., after-school program designed to help aspiring young entrepreneurs run their own businesses.
Mark Stautberg has more than 30 years of medical device sales & marketing experience. He held sales & marketing roles of increasing responsibility at SciMed Life Systems/Boston Scientific Corporation (BSC) for 14 years, most recently as Senior Vice President of Sales for the cardiovascular businesses from 1998-2004, where he grew revenues by ten times during his tenure as SVP. He was subsequently a consultant to BSC from 2004-2012. Prior to joining BSC, he held sales & marketing roles for 8 years at American Hospital Supply/Baxter Healthcare, including Director of Marketing. Mark currently serves on the board at Baxano Surgical (Minimally Invasive Spine) and previously served as a board member & consultant at Sealing Solutions (Vascular Sealing) and FlowCardia (CTO). Mark received a BBA in Marketing from the University of Cincinnati and has completed executive programs at Columbia University.
Eric Swanson brings more than 30 years of technical and operational experience to his position on NinePoint’s board of directors. He is a founding board member of both Acacia Communications and HiveFire Incorporated; an MIT research affiliate; a consultant for Draper Laboratory; and an advisor to high-tech startup companies in a wide range of technologies including biomedical imaging, optics, telecommunications, and Web technologies. Previously, Eric co-founded and was chief scientist and general manager at Sycamore Networks (public NASDAQ), co-founder and chief technology officer of LightLab Imaging (acquired by St. Jude Medical), and co-founder of Advanced Ophthalmic Devices (acquired by Carl Zeiss). Prior to that, he was an R&D group leader at MIT Lincoln Laboratory. Eric has authored more than 200 technical papers and conference presentations, holds numerous U.S. and foreign patents, and is a fellow of the OSA and senior member of the IEEE. He holds a BS degree in electrical engineering from UMass Amherst and an MS degree in electrical engineering from MIT.
Christopher von Jako brings extensive leadership and experience in the global medical device market with a specific expertise in image guided technologies. He has spent over 20 years focusing on the development and commercialization of image-guided techniques to improve patient experience and outcomes. Most recently, Chris was the President and CEO of NeuroTherm, a medical device company that develops, manufactures, and markets state-of-the-art image-guided solutions for pain management. He successfully executed the divesture of NeuroTherm with his team in August 2014 to St. Jude Medical. Prior to that, Chris was the President of ActiViews, a privately held medical device company, which developed and marketed minimally invasive tools for Interventional Radiology. Prior to this, he worked in senior management positions at Integra LifeSciences, Covidien, Medtronic, and Radionics. Chris holds a PhD in Biomedical Sciences from the University of Pécs Medical School, a MS in Radiological Sciences and Technology from the department of Nuclear Engineering at the Massachusetts Institute of Technology, and a double BS degree in Physics and Mathematics from Bates College.
Curt Weinstein has been vice president and general manager, Advanced Optics, Corning Specialty Materials, since August 2009. In this role, he is responsible for delivering profitable growth in the Optics, Specialty Glass, Optical Materials and Laser Technologies businesses. Weinstein joined Corning in 1986 as an applications engineer in Optical Fiber, and subsequently held leadership positions in sales, marketing, and product line management in both Optical Fiber and Photonic Technologies.
In March 2003, he was named business manager for Diesel Technologies. In July 2005, he was named general manager, Corning Shanghai Company Limited, where he was responsible for commercial and manufacturing operations. He was named director for Heavy-Duty Diesel in October 2007 and vice president and general manager, Heavy-Duty Diesel Technologies, in January 2008.
Weinstein holds a bachelor’s degree in physics from Georgetown University, a mechanical engineering degree from Catholic University of America, and a Master of Business Administration from Syracuse University.